&l;p&g;Everyone wants to see Alzheimer&a;rsquo;s disease cured; and certainly theories abound regarding its cause and a potential cure. But what puzzles even more of us and concerns physicians and scientists alike are the host of products being sold that claim to prevent or treat memory loss without any hardcore old-fashioned science to back it up. In fact, the concern is so great that the Alzheimer&a;rsquo;s Association&a;mdash;the world&a;rsquo;s leading voluntary health organization in Alzheimer&s;s care, support and research&a;mdash;has compiled a &l;a href=&q;https://www.alz.org/alzheimers_disease_alternative_treatments.asp&q; target=&q;_blank&q;&g;list&l;/a&g; of these alternative medicines and the hard truth behind them.
They&a;rsquo;re everywhere. Herbal remedies, dietary supplements and &q;medical foods&q;&a;nbsp;being promoted as memory enhancers or treatments to delay or prevent Alzheimer&a;rsquo;s disease and &l;a href=&q;https://www.alz.org/dementia/types-of-dementia.asp&q; target=&q;_blank&q;&g;related dementias&l;/a&g;. But the Alzheimer&a;rsquo;s Association is reminding a desperate public that claims about the safety and effectiveness of these products are &a;ldquo;based largely on testimonials, traditionand a rather small body of scientific research.&a;rdquo;
Hot Medical Stocks To Invest In Right Now: Cracker Barrel Old Country Store Inc.(CBRL)
- [By Asit Sharma]
If you’ve driven on a highway in the South or Midwest, you’ve probably seen billboards for Cracker Barrel (NASDAQ:CBRL) — and that’s part of what makes Cracker Barrel such a compelling buy.
- [By Motley Fool Staff]
Cracker Barrel (NASDAQ:CBRL) has treated its shareholders with a huge dose of southern hospitality, as shares have gained 24% annually on a total return basis over the last five years. The organization’s relatively stable business model of attracting recurring restaurant visits from highway travelers, and enticing them to visit adjoining gift stores, implies a level of safety versus faster-growth companies. Still, red flags exist, and in the following segment from a recent Motley Fool Industry Focus podcast, we outline problem areas investors should be aware of.
- [By Stephan Byrd]
Waratah Capital Advisors Ltd. decreased its position in Cracker Barrel (NASDAQ:CBRL) by 94.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,675 shares of the restaurant operator’s stock after selling 45,017 shares during the quarter. Waratah Capital Advisors Ltd.’s holdings in Cracker Barrel were worth $426,000 at the end of the most recent reporting period.
Hot Medical Stocks To Invest In Right Now: Aerohive Networks, Inc.(HIVE)
- [By Max Byerly]
Leidos (NYSE: LDOS) and Aerohive Networks (NYSE:HIVE) are both aerospace companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.
- [By Logan Wallace]
Aerohive Networks Inc (NYSE:HIVE) was the target of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 573,420 shares, a drop of 35.3% from the May 31st total of 885,671 shares. Based on an average trading volume of 381,201 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.8% of the shares of the stock are short sold.
- [By ]
Our Biggest Loser… And A Bunch Of Big Wins
Our biggest loser was back in January when we closed out of small communications equipment firm Aerohive Networks (Nasdaq: HIVE). On January 17, the company made a statement about its upcoming fourth-quarter earnings release, warning that revenue would likely be near the lower end of its guidance range. Investors didn’t take kindly to the news and sent shares tumbling by roughly 30%… well below our 15% trailing stop-loss. We ended up closing out with a 35% loss on the trade.
- [By Stephan Byrd]
Here are some of the news articles that may have effected Accern’s rankings:
Get Anthera Pharmaceuticals alerts:
Cystic Fibrosis Drugs Market – Future Growth Prospects and Industry Trends Analyzed Till 2025 (digitaljournal.com) Analysts Anticipate Anthera Pharmaceuticals Inc (ANTH) Will Announce Earnings of -$0.60 Per Share (americanbankingnews.com) News Buzz : Blink Charging Co. (NASDAQ:BLNK), Genocea Biosciences, Inc. (NASDAQ:GNCA), Anthera … (journalfinance.net) Current Lumpy Stocks:: Jounce Therapeutics, Inc. (NASDAQ:JNCE), Aerohive Networks, Inc. (NYSE:HIVE), Anthera … (journalfinance.net) Porous, non-porous tantalum cups yielded similar septic, aseptic risks after revision THA (healio.com)
ANTH has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research report on Tuesday, February 13th. Jefferies Financial Group reiterated a “hold” rating and set a $0.50 target price on shares of Anthera Pharmaceuticals in a research report on Thursday, March 15th. Roth Capital initiated coverage on Anthera Pharmaceuticals in a research report on Wednesday, February 21st. They set a “buy” rating and a $10.00 target price on the stock. Finally, Piper Jaffray Companies downgraded Anthera Pharmaceuticals from an “overweight” rating to an “underweight” rating in a research report on Monday, March 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $3.44.
Hot Medical Stocks To Invest In Right Now: Village Super Market Inc.(VLGEA)
- [By Joseph Griffin]
Media stories about Village Super Market, Inc. Class A (NASDAQ:VLGEA) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Village Super Market, Inc. Class A earned a news impact score of 0.06 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 43.9608995956738 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
- [By Logan Wallace]
Village Super Market, Inc. Class A (NASDAQ: VLGEA) and Koninklijke Ahold (OTCMKTS:ADRNY) are both retail/wholesale companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.
- [By Ethan Ryder]
BidaskClub lowered shares of Village Super Market (NASDAQ:VLGEA) from a hold rating to a sell rating in a report published on Tuesday.
Shares of VLGEA stock opened at $27.20 on Tuesday. Village Super Market has a 52-week low of $21.95 and a 52-week high of $31.49. The company has a quick ratio of 1.38, a current ratio of 1.81 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $392.70 million, a price-to-earnings ratio of 13.80 and a beta of 0.04.
- [By Shane Hupp]
BidaskClub upgraded shares of Village Super Market (NASDAQ:VLGEA) from a sell rating to a hold rating in a research report report published on Tuesday.
Hot Medical Stocks To Invest In Right Now: OncoCyte Corporation(OCX)
- [By Lisa Levin] Gainers
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares surged 144.96 percent to close at $265.61 on Thursday in reaction to an encouraging Phase 2 clinical trial update. The clinical-stage biopharmaceutical company said its liver-directed, thyroid hormone receptor called MGL-3196 showed a statistical significance in the primary endpoint of lowering liver fat at 12 weeks and also 36 weeks.
Viking Therapeutics, Inc. (NASDAQ: VKTX) shares rose 101.01 percent to close at $9.99 on Thursday after falling 4.42 percent on Wednesday.
Akers Biosciences, Inc. (NASDAQ: AKER) jumped 45.58 percent to close at $0.474. The developer of rapid health information technologies said Wednesday afternoon it was granted a 180-day extension from the Nasdaq Stock Market to meet the requirement of a minimum $1.00 per share closing bid price for 10 straight days.
Kitov Pharma Ltd (NASDAQ: KTOV) gained 40.93 percent to close at $3.03 after the FDA approved Kitov's Consensi for the treatment of osteoarthritis pain and hypertension.
China Customer Relations Centers, Inc. (NASDAQ: CCRC) rose 28.21 percent to close at $19.86.
J.Jill, Inc. (NYSE: JILL) climbed 26.45 percent to close at $7.84 after the company posted upbeat quarterly earnings.
Curis, Inc. (NASDAQ: CRIS) shares climbed 21.93 percent to close at $2.78 in reaction to an encouraging FDA update. The biotechnology company that focuses on therapies for the treatment of cancer said the FDA granted a Fast Track designation for fimepinostat (CUDC-907) in patients with relapsed or refractory.
Boxlight Corporation (NASDAQ: BOXL) gained 21.23 percent to close at $7.48.
Kirkland's, Inc. (NASDAQ: KIRK) rose 16.21 percent to close at $12.83 after reporting upbeat Q1 results.
The Brink's Company (NYSE: BCO) jumped 16.2 percent to close at $79.25 as the company announced plans to acquire Dunbar Armored for $520 million in cash.
Applied Optoelectronics, Inc. (NASDAQ: AAOI) rose 15.14 percent to c
- [By Jon C. Ogg]
OncoCyte Corp. (NYSE: OCX) was started as Overweight with a $6 price target (versus a $3.84 close) at Piper Jaffray. It has a 52-week range of $1.10 to $6.92 and a market cap of only $191 million.
- [By Money Morning News Team]
You only have to review the one-week gains of some of the top penny stocks to see how much investors can benefit. The top performer recently, OncoCyte Corp. (NYSE: OCX), skyrocketed almost 160% on the week. Yet it can still be purchased at only $4.98 per share.
- [By Lisa Levin]
Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
Arcadia Biosciences, Inc. (N
- [By Money Morning Staff Reports]
Just look at last week’s big winner, OncoCyte Corp. (NYSE: OCX). The stock surged nearly 160% in less than a week, and it still trades for just $4.98 a share.